Expressive

rs1042136 - HLA-DPB1

Magnitude 2.2 · 1 study on file

Reported associations

  • Clustering of lymphoid neoplasms by cell of origin, somatic mutation and drug usage profiles: a multi-trait genome-wide association study - Unknown journal (n.d.) · Unknown authors · PubMed 40883272

    ABSTRACT: Lymphoid neoplasms (LNs) are heterogeneous malignancies arising from lymphoid cells, displaying diverse clinical and molecular features. Although LNs are collectively frequent, individual subtypes are rare, posing challenges for genetic association studies. Indeed, genome-wide association studies (GWAS) explained only a fraction of the heritability. Shared genetic susceptibility and overlapping risk factors suggest a partially common etiology across subtypes. We employed a multi-trait GWAS strategy to improve discovery power by leveraging pleiotropy among LN subtypes. We defined LN phenoclusters based on cell of origin, somatic mutation profiles, and approved therapeutic agents. Using data from three large cohorts-the UK Biobank, Million Veteran Program, and FinnGen-we analyz

Auto-generated from study metadata. AI-synthesised commentary is added when this entry is regenerated through content-service's LLM mode.

Lifestyle context

Concrete actions anchored to the cited research. We do not prescribe, we describe.

Discuss with your doctor

  • AERD genetic risk and safe analgesic alternatives Moderate

    Documented genetic association (OR 3.28, p=3.4e-8) warrants clinical discussion of aspirin sensitivity and identification of safe pain management strategies.

    Bring genetic results to appointment; discuss aspirin challenge testing if diagnostic status remains unclear

Drug interactions

  • aspirin and other NSAIDs Moderate

    HLA-DPB1 I94L variant (CC/AC genotypes) is associated with 3.28-fold increased AERD risk; amino acid change at position 94 in the peptide binding site alters antigen presentation affecting aspirin tolerance.

Screening

  • respiratory and allergic symptoms after NSAID use Moderate

    AERD manifests as acute bronchospasm, nasal congestion, urticaria/angioedema within 30 min to 4 hours of NSAID ingestion due to altered immune recognition of aspirin metabolites.

    Report dyspnea, wheezing, nasal blockage, or rash occurring after aspirin/NSAID use to physician immediately